[Endoscopic treatment of bleeding ulcers: has everything been said and done?]

Gastroenterol Hepatol. 2005 Jun-Jul;28(6):347-53. doi: 10.1157/13076353.
[Article in Spanish]

Abstract

Endoscopic treatment reduces bleeding recurrence, the need for surgery and mortality in patients with bleeding ulcers. However endoscopic treatment fails in 10-15% of patients, leading to high morbidity and mortality. The therapeutic measures with demonstrated effectiveness in reducing the risk of hemorrhagic recurrence and its complications are combined endoscopic treatment (adrenaline plus a second hemostatic intervention) and proton pump inhibitors. Also useful, although there is less evidence, are immediate resuscitation and <<second look>> endoscopy. Some studies suggest that activated recombinant factor VII infusion or supra-selective arterial embolization can be useful in severe hemorrhage. Further studies are required to determine optimal treatment according to the characteristics of each patient.

Publication types

  • Review

MeSH terms

  • Anti-Ulcer Agents / therapeutic use
  • Case Management
  • Cohort Studies
  • Combined Modality Therapy
  • Duodenoscopy*
  • Epinephrine / therapeutic use
  • Evidence-Based Medicine
  • Factor VII / therapeutic use
  • Factor VIIa
  • Forecasting
  • Gastroscopy*
  • Humans
  • Meta-Analysis as Topic
  • Peptic Ulcer Hemorrhage / drug therapy
  • Peptic Ulcer Hemorrhage / surgery*
  • Proton Pump Inhibitors
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Resuscitation
  • Second-Look Surgery

Substances

  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Recombinant Proteins
  • Factor VII
  • recombinant FVIIa
  • Factor VIIa
  • Epinephrine